Kanawha Capital Management buys $11,198,056 stake in Becton Dickinson and Co (BDX)

Becton Dickinson and Co (BDX) : Kanawha Capital Management scooped up 2,335 additional shares in Becton Dickinson and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 25, 2016. The investment management firm now holds a total of 69,441 shares of Becton Dickinson and Co which is valued at $11,198,056.Becton Dickinson and Co makes up approximately 1.91% of Kanawha Capital Management’s portfolio.

Becton Dickinson and Co closed down -0.36 points or -0.22% at $160.9 with 12,77,475 shares getting traded on Monday. Post opening the session at $160.67, the shares hit an intraday low of $157.6 and an intraday high of $162.24 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Other Hedge Funds, Including , Washington Trust Bank reduced its stake in BDX by selling 11 shares or 30.56% in the most recent quarter. The Hedge Fund company now holds 25 shares of BDX which is valued at $4,032. Centurylink Investment Management Co sold out all of its stake in BDX during the most recent quarter. The investment firm sold 2,446 shares of BDX which is valued $391,066.Trillium Asset Management reduced its stake in BDX by selling 792 shares or 2.8% in the most recent quarter. The Hedge Fund company now holds 27,475 shares of BDX which is valued at $4,392,703. Becton Dickinson and Co makes up approx 0.29% of Trillium Asset Management’s portfolio.Gillespie Robinson Grimm Inc reduced its stake in BDX by selling 5,909 shares or 3.67% in the most recent quarter. The Hedge Fund company now holds 155,282 shares of BDX which is valued at $24,826,486. Becton Dickinson and Co makes up approx 3.95% of Gillespie Robinson Grimm Inc’s portfolio.

On the company’s financial health, Becton Dickinson and Co reported $1.96 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $1.84. The company had revenue of $2986.00 million for the quarter, compared to analysts expectations of $3034.79 million. The company’s revenue was up 45.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.53 EPS.

Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Upgraded by Deutsche Bank on Feb 11, 2016 to ” Buy”, Firm has raised the Price Target to $ 163 from a previous price target of $155 .Shares were Reiterated by RBC Capital Mkts on Feb 4, 2016 to “Sector Perform” and Lowered the Price Target to $ 153 from a previous price target of $162 .

Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.

Leave a Reply

Becton Dickinson and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Becton Dickinson and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.